These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. What's new in the treatment of metastatic kidney cancer? Mancuso A; Sternberg CN BJU Int; 2005 Jun; 95(9):1171-80. PubMed ID: 15892796 [No Abstract] [Full Text] [Related]
4. Immunotherapy for renal cell cancer. Yang JC; Childs R J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic approaches for renal cancer. Pizza G; de Vinci C; Viza D Folia Biol (Praha); 2002; 48(5):167-81. PubMed ID: 12448765 [No Abstract] [Full Text] [Related]
6. Current immunotherapeutic strategies in renal cell carcinoma. Amato RJ Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554 [TBL] [Abstract][Full Text] [Related]
7. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy. Kwan KG; Kapoor A Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804 [TBL] [Abstract][Full Text] [Related]
8. [New treatments for renal cell carcinoma: hope and limits]. Bodner A; Pelte MF; Verbist MC; Dietrich PY Rev Med Suisse; 2007 May; 3(112):1288, 1290-2, 1294 passim. PubMed ID: 17596064 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of metastatic renal cell cancer. Fishman M; Seigne J Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755 [TBL] [Abstract][Full Text] [Related]
11. A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. Srinivas S; Guardino AE BJU Int; 2005 Sep; 96(4):536-9. PubMed ID: 16104906 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous adrenalectomy during radical nephrectomy for renal cell carcinoma will not cure patients with adrenal metastasis. von Knobloch R; Schrader AJ; Walthers EM; Hofmann R Urology; 2009 Feb; 73(2):333-6. PubMed ID: 19038420 [TBL] [Abstract][Full Text] [Related]
13. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma. Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012 [TBL] [Abstract][Full Text] [Related]
14. [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies]. Ferrière JM; Wallerand H; Bernhard JC; Cornu JN; Rouprêt M; Ravaud A Prog Urol; 2008 Jul; 18 Suppl 4():S88-91. PubMed ID: 18706377 [TBL] [Abstract][Full Text] [Related]
15. Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer. Dillman RO; Beutel LD; Cornforth AN; Nayak SK Cancer Biother Radiopharm; 2000 Apr; 15(2):161-8. PubMed ID: 10803321 [TBL] [Abstract][Full Text] [Related]
16. Novel immunotherapy in metastatic renal cell carcinoma. Cho YH; Kim MS; Chung HS; Hwang EC Investig Clin Urol; 2017 Jul; 58(4):220-227. PubMed ID: 28681030 [TBL] [Abstract][Full Text] [Related]
17. Open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery. Dave DS; Lam JS; Leppert JT; Belldegrun AS BJU Int; 2005 Dec; 96(9):1268-74. PubMed ID: 16287443 [No Abstract] [Full Text] [Related]
18. New therapeutic developments in renal cell cancer. Prenen H; Gil T; Awada A Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971 [TBL] [Abstract][Full Text] [Related]